Bristol Erbitux Ultimatum: Company Wants Control Of FDA Negotiations

Bristol-Myers Squibb wants responsibility for the regulatory and clinical future of Erbitux under a proposed restructuring of the company's relationship with ImClone

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet